FY2025 · ended Dec 31, 2025 · Revenue $4.71M, +8.3% YoY · Filed Mar 25, 2026
Lucid Diagnostics Inc. (LUCD) files with the SEC under industry code 3841, Surgical & Medical Instruments & Apparatus. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $4.7 million and a net loss of $58.0 million. Free cash flow was -$46.7 million. As of Jun 30, 2026 it held $33.4 million in cash and investments and $1.4 million in total debt.
Revenue (TTM)
$5.45M
+24.9% vs year-ago TTM
Net income (TTM)
$-52.26M
+5.4% vs year-ago TTM
Operating cash flow (TTM)
$-46.87M
-8.8% vs year-ago TTM
Free cash flow
$-46.68M
-42.0% vs prior year
EPS
$-1.05
+16.7% vs prior year
Dividend per share
None
Shares outstanding
176.95M
+95.0% vs prior year
Net cash
$32.00M
as of Jun 30, 2026
Operating margin
-930.8%
FY 2026
Company profile
- Industry
- Surgical & Medical Instruments & Apparatus (SIC 3841)
- Listed as
- LUCD (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- New York, NY
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1799011
Other Surgical & Medical Instruments & Apparatus companies
- Stryker Corp SYK
- 3M Co MMM
- Boston Scientific Corp BSX
- Becton Dickinson & Co BDX
- Medline Inc. MDLN
- Resmed Inc RMD
- Dexcom Inc DXCM
- Fresenius SE & Co. KGaA FSNUY
All 151 Surgical & Medical Instruments & Apparatus companies
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $4.7M | $4.3M | $2.4M | $377,000 | $500,000 |
| Operating income | -$49.6M | -$46.1M | -$48.5M | -$56.3M | -$27.4M |
| Net income | -$58.0M | -$45.5M | -$52.7M | -$56.2M | -$28.1M |
| Diluted EPS | — | -$1.05 | -$1.26 | — | — |
| Operating cash flow | -$46.5M | -$44.1M | -$32.8M | -$29.7M | -$17.7M |
| Free cash flow | -$46.7M | — | — | -$32.9M | -$18.5M |
| Total assets | $40.4M | $30.7M | $27.3M | $32.5M | $59.0M |
| Total liabilities | $29.5M | $25.3M | $29.6M | $9.5M | $4.3M |
| Stockholders' equity | $10.9M | $5.4M | -$2.3M | $23.0M | $54.7M |
| Cash and investments | $34.7M | $22.4M | $18.9M | — | $53.7M |
| Total debt | $1.8M | $2.7M | $1.3M | $2.0M | — |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Unregistered share sale, Change to shareholder rights, Bylaw or fiscal year change
|
Oct 22, 2026 | Oct 21, 2026 |
| 8-K |
Current report
Listing notice
|
Oct 16, 2026 | Oct 12, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Sep 22, 2026 | Sep 22, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Aug 13, 2026 | Aug 13, 2026 |
| 10-Q | Quarterly report | Aug 12, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Bylaw or fiscal year change, Shareholder vote results
|
Jun 24, 2026 | Jun 24, 2026 |
All 281 Lucid Diagnostics Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.